Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Kenneth J. Widder
AddedFeb 19, 2024
UpdatedMay 31, 2026
Kenneth J. Widder

Kenneth J. Widder

CEO, Sydnexis

Crunchbase

Kenneth J. Widder's Career

Sydnexis
Sydnexis

Del Mar, CA, US

CEO· C-Suite · Management
Naurex
Naurex

Evanston, IL, US

Board Member· Board
Evoke Pharma
Evoke Pharma

Solana Beach, CA, US

Board Member· Board
Personalis
Personalis

Menlo Park, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Kenneth J. Widder's Career

Sydnexis
Sydnexis
Series B$50.5M332014Del Mar, CA, US
CEO· C-Suite · Management

Leadership at Sydnexis

Gregory OstrowGregory OstrowFounder
Gregory GrunbergGregory GrunbergBoard Member
Zach ScheinerZach ScheinerBoard Member

Similar to Sydnexis

Visus TherapeuticsVisus TherapeuticsSeattle, WA, USEye Dropsest. 2019Visus TherapeuticsSeattle, WA, US · est. 2019

Visus Therapeutics: Pioneering presbyopia-correcting eye drops with 8-hour potential.

Series B · $56M45
Nexis VisionNexis VisionMenlo Park, CA, USEye Solutionsest. 2007Nexis VisionMenlo Park, CA, US · est. 2007

Innovative biotech creating eye solutions for surgery and diseases.

Pre-Seed · $34.8M6
OcuTerra TherapeuticsOcuTerra TherapeuticsBoston, MA, USEye Dropsest. 2011OcuTerra TherapeuticsBoston, MA, US · est. 2011

OcuTerra develops innovative eye-drop, OTT166, for efficient, early treatment of diabetic eye disease.

Series B · $35M11
Treehouse EyesTreehouse EyesBoulder, CO, USEye Care, Myopia Treatmentest. 2015Treehouse EyesBoulder, CO, US · est. 2015

Treehouse offers top-tier myopia treatments for kids, led by expert optometrists and ophthalmologists, prioritizing child eye care.

Series A · $8.2M23
Naurex
Naurex
Acquired$162.1M02008Evanston, IL, US
Board Member· Board

Leadership at Naurex

Bill GantzBill GantzBoard Member
Joseph MoskalJoseph MoskalFounder
Norbert RiedelNorbert RiedelBoard Member
Terry GouldTerry GouldBoard Member
Xavier HovasseXavier HovasseBoard Member
Li HaiyanLi HaiyanBoard Member

Similar to Naurex

Neurana PharmaceuticalsNeurana PharmaceuticalsSan Diego, CA, USPharmaceuticalsest. 2013Neurana PharmaceuticalsSan Diego, CA, US · est. 2013

Neurana Pharmaceuticals: A US-based specialty pharma company innovating treatments for CNS diseases.

Series A · $60M5
NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
CeNeRx BiopharmaCeNeRx BiopharmaCary, NC, USNeurology Drugsest. 2005CeNeRx BiopharmaCary, NC, US · est. 2005

CeNeRx BioPharma develops neurology drugs, focusing on treatments for depression and anxiety.

Series A · $59.3M6
AptinyxAptinyxEvanston, IL, USPharmaceuticalsest. 2015AptinyxEvanston, IL, US · est. 2015

Aptinyx Inc., a US-based bio-pharmaceutical company, specializes in developing novel treatments for brain and nervous system disorders.

Public · $273.9M12
Evoke Pharma
Evoke Pharma
Public$28.2M52007Solana Beach, CA, US
Board Member· Board

Leadership at Evoke Pharma

Dave GonyerDave GonyerBoard Member
Vickie ReedVickie ReedBoard Member
Todd C. BradyTodd C. BradyBoard Member
Malcolm R. HillMalcolm R. HillBoard Member
Cam L. GarnerCam L. GarnerBoard Member
Personalis
Personalis
Public$225.1M3992011Menlo Park, CA, US
Board Member· Board

Leadership at Personalis

Woodrow MyersWoodrow MyersBoard Member
Alan ColowickAlan ColowickBoard Member
Christopher SchaepeChristopher SchaepeBoard Member
Euan AshleyEuan AshleyBoard Member
Jonathan MacQuittyJonathan MacQuittyBoard Member
Vincent MilesVincent MilesBoard Member

Kenneth J. Widder's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Kenneth J. Widder

Karin EasthamKarin EasthamBoard Member · VeracyteJeff MellenJeff MellenCo-Founder · dynacrowdJames WinkelmanJames WinkelmanCo-Founder · ClearItKen ReedKen ReedCo-Founder · EarlyCellJenny YipJenny YipBoard Member · Antiva BiosciencesStephane MouradianStephane MouradianBoard Member · Arboretum Ventures